| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 1
| Issue : 1 | Page : 9-13 |
|
|
A review of current clinical studies leading to improved outcomes in patients treated with newer-generation thrombectomy devices
Yaser Carcora1, Mohammed Hussain1, Xiaokun Geng2, Yuchuan Ding2
1 Department of Neurological Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA
2 Department of Neurological Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA; Department of Neurology, China-America Institute of Neuroscience, Luhe Hospital, Capital Medical University, Beijing, China
Correspondence Address:
Yuchuan Ding
Department of Neurological Surgery, Wayne State University School of Medicine, 550 E Canfield, Detroit - 48201, Michigan, USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2394-8108.166352
|
|
|
Treatment with endovascular treatment in conjunction with intra-venous Tissue Plasminogen Activator (IV tPA) under specific clinical situations leads to improved functional outcomes in patients. This review addresses the efficacy of endovascular stroke treatment in patients selected under ideal inclusion criteria and treated with the most up to date embolectomy devices. Recent trials such as ESCAPE, MR CLEAN, EXTEND IA and SWIFT PRIME showed that demonstration of proximal vessel occlusion in CT scans, stratification of penumbral patterns, along with expedient recanalization with the most up to date embolectomy devices leads to a statistically significant improvement in function, NIHSS scores, and mortality in patients treated with endovascular tPA. SWIFT PRIME, in particular, demonstrated that patients demonstrated a 4.5 point improvement in NIHSS scores 27 hours after treatment and decreased mortality along with an increased number of patients with a Rankin score of 1-2 90 days after therapy. Evidence shows that endovascular stroke treatment leads to improved outcomes in patients who are selected based on refined CT guided inclusion criteria and rapid revascularization by newer generation embolectomy devices in conjunct with IA tPA. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
